Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER Drug Safety Website Model Includes Elidel; Novartis Objects

Executive Summary

Novartis objects to the inclusion of its eczema therapy Elidel in FDA's drug safety website model

You may also be interested in...



FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed

FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September

FDA Phasing In Restructuring Of Drug Office; Move To White Oak Postponed

FDA is proceeding with the restructuring of the Office of New Drugs ahead of a formal switch to the new organization in September

FDA Rx Safety Website Will Include Drugs With Emerging Off-Label Issues

FDA's "Drug Watch" website will include safety information on drugs that have emerging safety signals for off-label uses

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel